Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company ...(t with our second generation techn...)

with our second generation technologies.

Progressed our preclinical programs in regenerative therapeutics,

neurodegenerative disease and molecular imaging.

-- Data from a rodent study designed to measure the levels of Inosine in

the brain during intravenous infusion of high concentrations of Inosine

were presented at the American Society for Experimental

NeuroTherapeutics (ASENT). This study showed that, when administered

intravenously using a new, high concentration formulation of Inosine,

Inosine levels in the brain increased more than 600% over baseline

levels. Inosine is a nerve regenerative factor that has been shown to

promote axon outgrowth in neurons and has potential to be used to treat

CNS disorders such as spinal cord injury, stroke, and traumatic brain

injury.

-- Findings from a study to determine brain bioavailability following oral

administration of three of Alseres' highly-selective dopamine

transporter (DAT) blockers were also presented at the ASENT meeting.

The data presented showed that all three of the Company's DAT blockers

given orally were rapidly absorbed into the blood and the brain and

provided favorable brain-to-blood plasma ratios.

-- Working with our scientific collaborators, we initiated a series of

comparative studies in which other of our regenerative technologies,

including Inosine, Oncomodulin and other compounds, are being tested in

parallel in a series of models of CNS disorders to assess their

potential to enhance nerve repair. If successful, these studies may

enable the most promising candidates and indications to be taken

forward in development.

-- We are also evaluating our Rho inhibitors in animal models to assess

their ability to stimulate cells to regenerate bone. It is estimate
'/>"/>